Insider · CIK 0001665124
Sukumar Nagendran
Files at SLDB (Solid Biosciences Inc.), TSHA (Taysha Gene Therapies, Inc.). First filing Aug 22, 2025, latest Jul 10, 2026.
In brief
Sukumar Nagendran files SEC Form 4 as director and president at TSHA (Taysha Gene Therapies, Inc.), and also at SLDB (Solid Biosciences Inc.). Since Aug 22, 2025, Sukumar Nagendran has reported 0 open-market buys worth $0 and 7 open-market sells worth $6.1M, the latest filed on Jul 10, 2026.
A track record needs three past buys with six months of prices behind them; Sukumar Nagendran has 0, so none is measured yet.
The newest scored trade: sold $1.2M of TSHA on Jul 10, 2026, filed Jul 10, 2026, scored 30 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $5.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TSHA: Taysha Gene Therapies, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Taysha Gene Therapies, Inc. | $1.2M 200,000 shares | -18% | +153% from low-9% from high | |
| 13Weak | Taysha Gene Therapies, Inc. | $892k 200,000 shares | -15% | +284% from low-24% from high | |
| 54Moderate | Taysha Gene Therapies, Inc. | $547k 116,050 shares | -8% | +312% from low-21% from high | |
| 29Weak | Taysha Gene Therapies, Inc. | $942k 200,000 shares | -17% | +330% from low-18% from high | |
| 40Moderate | TSHAsell Taysha Gene Therapies, Inc. | $1.7M 370,172 shares | -33% | - | |
| 10Weak | Taysha Gene Therapies, Inc. | $646k 200,000 shares | -17% | - | |
| 39Weak | Taysha Gene Therapies, Inc. | $163k 57,054 shares | -5% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 10, 2026 | TSHA Taysha Gene Therapies, Inc. | 200,000 0.06% of outstanding | $1.3M | Jul 10, 2026 | $831k |
| Apr 10, 2026 | TSHA Taysha Gene Therapies, Inc. | 200,000 0.07% of outstanding | $926k | Apr 10, 2026 | $943k |
| Jan 23, 2026 | TSHA TAYSHA GENE THERAPIES, INC. | 113,824 0.04% of outstanding | $579k | Jan 23, 2026 | $1.5M |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | 200,000 0.07% of outstanding | $996k | Jan 12, 2026 | $1.7M |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | 370,172 0.14% of outstanding | $1.8M | Nov 28, 2025 | $646k |
| Sep 10, 2025 | TSHA Taysha Gene Therapies, Inc. | 200,000 0.07% of outstanding | $652k | Sep 10, 2025 | $163k |
| Aug 21, 2025 | TSHA TAYSHA GENE THERAPIES, INC. | 57,054 0.02% of outstanding | $164k | Aug 21, 2025 | none |
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -200,000 | $6.24 | $1.2M | 936,410 | Jul 10, 2026 |
| Jun 10, 2026 | SLDB Solid Biosciences Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +77,500 | $0.00 | $0 | 77,500 | Jun 11, 2026 |
| Apr 10, 2026 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock10b5-1 | +19,021 | $1.71 | $33k | 1,336,410 | Apr 13, 2026 |
| Apr 10, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -200,000 | $4.46 | $892k | 1,136,410 | Apr 13, 2026 |
| Apr 10, 2026 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -19,021 | $0.00 | $0 | 455,920 | Apr 13, 2026 |
| Jan 23, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -89,132 | $4.75 | $423k | 1,344,307 | Jan 27, 2026 |
| Jan 26, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -26,918 | $4.61 | $124k | 1,317,389 | Jan 27, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock10b5-1 | +111,324 | $0.70 | $78k | 1,117,763 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock10b5-1 | +88,676 | $1.71 | $152k | 1,206,439 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -200,000 | $4.71 | $942k | 1,006,439 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Common Stock10b5-1 | +427,000 | $0.00 | $0 | 1,433,439 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -111,324 | $0.00 | $0 | 111,359 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -88,676 | $0.00 | $0 | 474,941 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative10b5-1 | +274,000 | $0.00 | $0 | 274,000 | Jan 14, 2026 |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock | +70,172 | $0.70 | $49k | 1,076,611 | Dec 1, 2025 |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock | +39,953 | $1.71 | $68k | 1,116,564 | Dec 1, 2025 |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -110,125 | $4.75 | $523k | 1,006,439 | Dec 1, 2025 |
| Dec 1, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock | +260,047 | $1.71 | $445k | 1,266,486 | Dec 1, 2025 |
| Dec 1, 2025 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -260,047 | $4.51 | $1.2M | 1,006,439 | Dec 1, 2025 |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -70,172 | $0.00 | $0 | 222,683 | Dec 1, 2025 |
| Nov 28, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -39,953 | $0.00 | $0 | 823,664 | Dec 1, 2025 |
| Dec 1, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -260,047 | $0.00 | $0 | 563,617 | Dec 1, 2025 |
| Sep 10, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Common Stock10b5-1 | +41,150 | $0.70 | $29k | 1,206,439 | Sep 12, 2025 |
| Sep 10, 2025 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -200,000 | $3.23 | $646k | 1,006,439 | Sep 12, 2025 |
| Sep 10, 2025 | TSHA Taysha Gene Therapies, Inc. | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -41,150 | $0.00 | $0 | 292,855 | Sep 12, 2025 |
| Aug 21, 2025 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -57,054 | $2.85 | $163k | 1,165,289 | Aug 22, 2025 |
| Jun 12, 2025 | SLDB Solid Biosciences Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +77,500 | $0.00 | $0 | 77,500 | Jun 13, 2025 |
| Dec 14, 2023 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +334,005 | $0.00 | $0 | 334,005 | Dec 18, 2023 |
Questions about Sukumar Nagendran
Answered from the filings on this page, as of the latest one.
Is Sukumar Nagendran buying or selling?
In the last 12 months Sukumar Nagendran reported 0 open-market buys worth $0 and 5 open-market sells worth $5.3M on SEC Form 4; the latest was sold $1.2M of TSHA on Jul 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Sukumar Nagendran's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sukumar Nagendran has 0.
Where does Sukumar Nagendran file Form 4?
Sukumar Nagendran has filed Form 4 at TSHA (Taysha Gene Therapies, Inc.) as President and Head of R&D; SLDB (Solid Biosciences Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.